Inegy (Simvastatin, Ezetimibe)

• Inegy is used to manage disorders of lipid metabolism and to reduce cardiovascular risk associated with elevated cholesterol levels.
• Primary hypercholesterolemia: lowers low‑density lipoprotein cholesterol (LDL‑C) to target levels.
• Mixed dyslipidemia: reduces LDL‑C and triglycerides while modestly increasing high‑density lipoprotein cholesterol (HDL‑C).
• Cardiovascular risk reduction: used as part of a comprehensive plan, including diet and lifestyle, to lower the risk of myocardial infarction and stroke in patients with elevated cholesterol.

• Simvastatin competitively inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol synthesis, leading to up‑regulation of LDL receptors and increased clearance of circulating LDL particles. Ezetimibe blocks the NPC1L1 transporter on enterocytes, decreasing intestinal absorption of dietary and biliary cholesterol. The combined effect produces a synergistic reduction in plasma LDL‑C and total cholesterol levels.

Inegy may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Muscle pain (myalgia): aching or soreness without weakness.
• Abdominal discomfort: including nausea or dyspepsia.
• Diarrhea: loose stools occurring intermittently.
• Elevated liver enzymes: mild transaminase increases detected on routine labs.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with dark urine.
• Acute liver injury: marked elevation of transaminases with jaundice.
• Severe allergic reaction: rash, angioedema, or anaphylaxis.
• Pancreatitis: abdominal pain with elevated pancreatic enzymes.
• Myopathy with weakness: muscle weakness accompanied by elevated CK levels.

Before initiating therapy, clinicians should assess baseline labs and patient risk factors.

• Liver function monitoring: obtain baseline and periodic ALT/AST measurements.
• Muscle symptom assessment: educate patients to report unexplained muscle pain or weakness.
• Drug interaction review: evaluate concomitant medications that affect CYP3A4 or cholesterol metabolism.
• Renal impairment caution: adjust therapy in patients with severe renal dysfunction.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Inegy interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ritonavir): increase simvastatin exposure.
• Gemfibrozil: markedly raises risk of myopathy and rhabdomyolysis.
• Cyclosporine: elevates both simvastatin and ezetimibe concentrations.
• High‑dose niacin: potentiates muscle toxicity.
• Antifungal azoles: potentiate statin levels.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Digoxin: potential increase in serum digoxin levels.
• Other fibrates (e.g., fenofibrate): monitor for muscle symptoms.
• Antacids containing aluminum/magnesium: may reduce ezetimibe absorption.
• Beta‑blockers: observe for additive lipid‑lowering effect.